Shock - Pipeline Review, H2 2012

Description: Shock – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Shock - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shock. Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Shock.
- A review of the Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Shock pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Shock pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2 List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Shock Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Shock 11
Shock Therapeutics under Development by Companies 13
Shock Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Shock Therapeutics – Products under Development by Companies 22
Shock Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Shock Therapeutics Development 24
Baxter International Inc. 24
Sangart, Inc. 25
Novo Nordisk A/S 26
Cytokine PharmaSciences, Inc. 27
Curacyte AG 28
Integrated BioTherapeutics, Inc. 29
Ikaria Inc. 30
Sihuan Pharmaceutical Holdings Group Ltd. 31
Shock – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 39
Hemoglobin Glutamer-250 Bovine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
IK-6003 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Hemoximer - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TREM-1 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
IK-6001 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
thiamine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
serum albumin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
estrone sodium sulfate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
epinephrine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Methylene Blue + Nitric Oxide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
hydrocortisone acetate - Drug Profile 52
Product Description 52
Featured News & Press Releases

Oct 08, 2012: Sangart Completes Patient Enrollment In Phase Ib Trial Of MP4OX In Traumatic Hemorrhagic Shock Patients

Aug 02, 2012: Oxygen Biotherapeutics And US Navy Expand Collaboration With CRADA To Study Oxycyte For Treatment Of Hemorrhagic Shock

Jul 28, 2011: Boston Therapeutics To Present Data On Ipoxyn At Symposium At Massachusetts General Hospital


Mar 28, 2011: PHOENIX Phase III Trial Of PHP For Distributive Shock To Continue After Positive Midpoint Recommendation From DMB

Apr 09, 2010: XOMA To Present Data On XOMA 052 At American Association of Cancer Research Annual Meeting

Dec 09, 2009: Sangart Initiates Phase Ii Study Of MP4OX In Trauma Patients With Hemorrhagic Shock

Jun 05, 2009: Curacyte Reports Enrollment Of First Patient In The PHOENIX Trial For The Drug Hemoximer


Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Route of Administration, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Molecule Type, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 37

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2335375/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Shock - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2335375/
Office Code: SCD2943W

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp